Document Detail


Effect of nisoldipine and olmesartan on endothelium-dependent vasodilation in essential hypertensive patients.
MedLine Citation:
PMID:  22533725     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS: To investigate whether nisoldipine and olmesartan improve endothelial function, decrease asymmetric dimethylarginine (ADMA) and alleviate the inflammatory and oxidative process.
METHODS: Fifty-five essential hypertensive patients were randomized to receive nisoldipine or olmesartan for 8 weeks according to a parallel-group, active-controlled, single blind study, and 28 matched normotensive subjects served as healthy controls. Flow-mediated dilation (FMD), and plasma levels of nitric oxide (NO), endothelin-1 (ET-1), high-sensitive C-reactive protein (hs-CRP), 8-isoprostane (also named 8-isoPGF2α), and ADMA were determined.
RESULTS: At baseline, the plasma levels of ADMA, ET-1, hs-CRP, and 8-isoPGF2α were markedly higher in patients with essential hypertension than in normotensive subjects (P < 0.05). A significant positive correlation was observed between plasma levels of ET-1 and ADMA in patients with essential hypertension, but not in normotensive subjects. The NO plasma concentrations were significantly lower in patients with essential hypertension than in normotensive subjects. Furthermore, hypertensive subjects demonstrated significantly lower FMD than healthy control (P < 0.05). Nisoldipine and olmesartan significantly and similarly reduced blood pressure in patients with essential hypertension (P < 0.001). At the end of the 8-week treatment, plasma ADMA and ET-1 levels were decreased significantly (P < 0.01). FMD increased significantly in nisoldipine or olmesartan-treated patients (P < 0.05). A significant decrease in plasma hs-CRP contents was observed in patients receiving nisoldipine (P < 0.05).
CONCLUSION: The findings demonstrate that nisoldipine and olmesartan both improve FMD in patients with essential hypertension. This may be associated with decreased circulating levels of CRP, ET-1, and ADMA.
Authors:
Duo Wei; Wan-Yuan He; Qian-Zhou Lv
Related Documents :
11425335 - Gonadotrophin-induced follicle development in red deer hinds during the breeding and no...
22533725 - Effect of nisoldipine and olmesartan on endothelium-dependent vasodilation in essential...
2119415 - Fsh causes a time-dependent stimulation of preovulatory follicle growth in the absence ...
19394185 - Influence of triiodothyronine (t(3)) on secretion of steroids and thyroid hormone recep...
6688695 - Thyroid function and bone turnover.
3688805 - The significance of candida-specific serum ige in recurrent vaginal candidiasis.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  CNS neuroscience & therapeutics     Volume:  18     ISSN:  1755-5949     ISO Abbreviation:  CNS Neurosci Ther     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-04-26     Completed Date:  2012-08-27     Revised Date:  2013-04-15    
Medline Journal Info:
Nlm Unique ID:  101473265     Medline TA:  CNS Neurosci Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  400-5     Citation Subset:  IM    
Copyright Information:
© 2012 Blackwell Publishing Ltd.
Affiliation:
Department of Pharmacy, Zhongshan, Hospital, Fudan University, Shanghai, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Anthracenes
Antihypertensive Agents / pharmacology*,  therapeutic use
Arginine / analogs & derivatives,  blood
Blood Pressure / drug effects
C-Reactive Protein / metabolism
Case-Control Studies
Endothelin-1 / blood
Endothelium / blood supply*,  drug effects
Female
Humans
Hypertension / blood,  drug therapy,  pathology*
Imidazoles / pharmacology*,  therapeutic use
Male
Middle Aged
Nisoldipine / pharmacology*,  therapeutic use
Nitric Oxide / blood
Propane / analogs & derivatives,  blood
Prostaglandins F / blood
Single-Blind Method
Tetrazoles / pharmacology*,  therapeutic use
Vasodilation / drug effects*
Chemical
Reg. No./Substance:
0/Anthracenes; 0/Antihypertensive Agents; 0/Endothelin-1; 0/Imidazoles; 0/Prostaglandins F; 0/Tetrazoles; 10102-43-9/Nitric Oxide; 30315-93-6/N,N-dimethylarginine; 34069-62-0/prostaglandin F-main urinary metabolite; 63675-72-9/Nisoldipine; 74-79-3/Arginine; 74-98-6/Propane; 8W1IQP3U10/olmesartan; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Kallikrein gene transfer induces angiogenesis and further improves regional cerebral blood flow in t...
Next Document:  Combination of low-dose bupivacaine and opioids provides satisfactory analgesia with less intraopera...